Updates in CheckMate-816 From ESMO 2023
Patrick Forde, MBBCh, discusses CheckMate-816 study results, including the high pathological complete response rates within 6 weeks of immunotherapy reported in the trial's third arm.
This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.
The experts discuss the CheckMate 816 trial, a study that tested neoadjuvant nivolumab plus chemotherapy for patients with resectable stage IB (≥ 4 cm tumor size) to IIIA non–small cell lung cancer using the American Joint Committee on Cancer 7th edition staging system. The combination led to significant improvements in event-free survival (EFS) and higher pathological complete response rates compared with chemotherapy alone.
Exploratory analyses presented at the European Society for Medical Oncology (ESMO) Congress 2023 showed EFS, overall survival, and pathological complete response rates benefits across PD-L1 expression subgroups (≥ 1% or < 1%), with a deeper magnitude of benefit in patients with higher PD-L1 expression (≥ 50%). These results reinforced the clinical benefit and manageable safety profile of neoadjuvant nivolumab plus chemotherapy, with PD-L1 expression and other factors potentially influencing treatment decisions.
The trial also included a third arm of nivolumab plus ipilimumab, which delivered high pathologic complete response rates (20%) and prolonged median EFS compared with chemotherapy. However, some patients experienced early progression, highlighting the continued role of chemotherapy in neoadjuvant and preoperative approaches. Combinations of chemotherapy with PD-1 and CTLA-4 inhibitors may be more beneficial than CTLA-4 and PD-1 inhibitors alone in early-stage disease.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
